HealthQuill
Harvard University has rejected demands from US President Donald Trump’s administration that threaten $9 billion in research funding.
Drugs Health Pharma

Harvard rejects Trump’s demands that threaten $9b research funding

HQ Team April 15, 2025: Harvard University has rejected demands from US President Donald Trump’s administration that threaten $9 billion in research funding..

Read More
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of the heart's main pumping chamber becomes abnormally thickened, has failed to meet its goals.
Drugs Health Medical

Bristol Myers’ test drug to treat a type of heart disease fails to meet goals

HQ Team April 15, 2025: Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of.

Read More
Cambridge researchers have invented a device to record heart sounds accurately and diagnose coronary valve diseases better than traditional stethoscopes.
Health Medical Pharma

Cambridge develops handheld device to detect faulty heart valves

HQ Team April 13, 2025: Cambridge researchers have invented a device to record heart sounds accurately and diagnose coronary valve diseases better than.

Read More
Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its coronary intravascular catheter for treating blocked arteries, according to a statement.
Health Medical Pharma

J&J starts trial on coronary pressure wave catheter to clear artery blocks

HQ Team April 13, 2025: Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its.

Read More
A new pandemic like Covid-19 is “not a theoretical risk, it is an epidemiological certainty,” said the World Health Organization’s Director-General, Dr Tedros Adhanom Ghebreyesus.
Climate Drugs Health

A new pandemic like Covid-19 is ‘epidemiological certainty’: WHO

HQ Team April 13, 2025: A new pandemic like Covid-19 is “not a theoretical risk, it is an epidemiological certainty,” said the World.

Read More
A European Space Agency satellite is slated for launch on April 29 to gather information about the state of global forests and how they are changing.
Climate Health Medical

European Space Agency set to launch satellite to map global forests

HQ Team April 12, 2025: A European Space Agency satellite is slated for launch on April 29 to gather information about the state.

Read More
A landmark deal to reduce greenhouse emissions from global shipping is set to be formally adopted in October before coming into force in 2027.
Climate Health Medical

Historic deal to cut global shipping emissions may take effect in 2027

HQ Team April 12, 2025: A landmark deal to reduce greenhouse emissions from global shipping is set to be formally adopted in October.

Read More
A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is underway in US research institutions as the overall disease population is expected to reach 783 million people by 2045.
Health Pharma

Dexcom’s 15-day G7 sensor for glucose monitoring wins FDA nod

HQ Team April 11, 2025: For people living with diabetes, glucose sensors for monitoring sugar levels are a game changer. The present ones.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Pharma

Novartis bets $23b on US as pharma giants brace for tariff storm

Swati Mishra April 11, 2025: “We are prepared for shifts in the external environment and fully confident in our growth outlook,” Novartis CEO Vas.

Read More